William Blair Predicts Weaker Earnings for LENZ Therapeutics

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Research analysts at William Blair cut their FY2025 earnings estimates for LENZ Therapeutics in a research report issued to clients and investors on Wednesday, November 5th. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn ($2.69) per share for the year, down from their previous estimate of ($2.61). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. William Blair also issued estimates for LENZ Therapeutics’ Q4 2025 earnings at ($1.00) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.79) EPS, Q3 2026 earnings at ($0.71) EPS, Q4 2026 earnings at ($0.60) EPS and FY2026 earnings at ($3.02) EPS.

LENZ Therapeutics (NASDAQ:LENZ) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.67) by $0.08. The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $4.64 million.

Several other equities analysts also recently issued reports on the company. Citigroup reiterated a “buy” rating and set a $49.00 price objective (up from $45.00) on shares of LENZ Therapeutics in a research report on Thursday, July 31st. HC Wainwright reiterated a “buy” rating and set a $56.00 price target on shares of LENZ Therapeutics in a research report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of LENZ Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of LENZ Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 22nd. Finally, Piper Sandler upped their price objective on shares of LENZ Therapeutics to $67.00 and gave the stock an “overweight” rating in a report on Friday, October 10th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $56.40.

LENZ Therapeutics Trading Up 0.0%

NASDAQ LENZ opened at $22.97 on Friday. The company has a 50-day moving average price of $38.39 and a two-hundred day moving average price of $33.83. LENZ Therapeutics has a 52 week low of $16.53 and a 52 week high of $50.40. The stock has a market cap of $718.73 million, a price-to-earnings ratio of -10.89 and a beta of 0.46.

Insider Buying and Selling at LENZ Therapeutics

In other LENZ Therapeutics news, CFO Daniel R. Chevallard purchased 2,198 shares of the stock in a transaction dated Friday, November 7th. The shares were acquired at an average price of $22.76 per share, for a total transaction of $50,026.48. Following the completion of the acquisition, the chief financial officer owned 5,386 shares of the company’s stock, valued at $122,585.36. This represents a 68.95% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On LENZ Therapeutics

A number of institutional investors have recently bought and sold shares of LENZ. Bfsg LLC purchased a new position in LENZ Therapeutics during the 3rd quarter valued at about $30,000. Osaic Holdings Inc. grew its position in LENZ Therapeutics by 2,146.2% during the second quarter. Osaic Holdings Inc. now owns 1,168 shares of the company’s stock valued at $34,000 after purchasing an additional 1,116 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in LENZ Therapeutics by 51.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,405 shares of the company’s stock valued at $41,000 after buying an additional 477 shares during the period. Ameritas Investment Partners Inc. lifted its position in LENZ Therapeutics by 47.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,817 shares of the company’s stock worth $53,000 after buying an additional 586 shares in the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of LENZ Therapeutics by 93.7% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,951 shares of the company’s stock valued at $57,000 after buying an additional 944 shares during the period. 54.32% of the stock is currently owned by institutional investors and hedge funds.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.